Activity
-
This development presents a number of interesting questions. First, as this compound is a dual agonist (GLP-1/GIP) shown by some studies to yield…
This development presents a number of interesting questions. First, as this compound is a dual agonist (GLP-1/GIP) shown by some studies to yield…
Liked by Huibin Yue
-
Welcome Angus Russell and congratulations to Structure Therapeutics
Welcome Angus Russell and congratulations to Structure Therapeutics
Liked by Huibin Yue
-
Next month, our team will participate in fireside chats at both the Morgan Stanley 22nd Annual Global Healthcare Conference and Cantor Fitzgerald's…
Next month, our team will participate in fireside chats at both the Morgan Stanley 22nd Annual Global Healthcare Conference and Cantor Fitzgerald's…
Liked by Huibin Yue
More activity by Huibin
-
The start of something great. Welcome home to our newest Hawkeyes! 💛🖤
The start of something great. Welcome home to our newest Hawkeyes! 💛🖤
Liked by Huibin Yue
-
In a recent interview with Meijing Wu and Di Zhang for the "Biopharmaceutical Report," industry leaders Ivan Chan and Bill Wang discuss the crucial…
In a recent interview with Meijing Wu and Di Zhang for the "Biopharmaceutical Report," industry leaders Ivan Chan and Bill Wang discuss the crucial…
Liked by Huibin Yue
-
It takes so little effort to acknowledge someone's contributions, yet its impact can be immeasurable. That’s why we launched our internal global…
It takes so little effort to acknowledge someone's contributions, yet its impact can be immeasurable. That’s why we launched our internal global…
Liked by Huibin Yue
-
I’m excited to welcome Gregory Friberg and James Sabry to the BioMarin Leadership Team (BLT) in the coming weeks. I would also like to thank our…
I’m excited to welcome Gregory Friberg and James Sabry to the BioMarin Leadership Team (BLT) in the coming weeks. I would also like to thank our…
Liked by Huibin Yue
-
We are delighted to announce the appointment of Mike Powell and Chris Bowden to our board of directors. Both individuals are esteemed leaders in the…
We are delighted to announce the appointment of Mike Powell and Chris Bowden to our board of directors. Both individuals are esteemed leaders in the…
Liked by Huibin Yue
-
Well, JSM 2024 is a wrap! It was great seeing everyone in Portland! Always nice to see so many familiar faces (candidates, clients, &…
Well, JSM 2024 is a wrap! It was great seeing everyone in Portland! Always nice to see so many familiar faces (candidates, clients, &…
Liked by Huibin Yue
-
Today we announced results from Q2 2024, a pivotal time for our team. Our key progress included the Phase 2a #obesity results demonstrating GSBR-1290…
Today we announced results from Q2 2024, a pivotal time for our team. Our key progress included the Phase 2a #obesity results demonstrating GSBR-1290…
Liked by Huibin Yue
-
After 21 amazing years at Roche/Genentech, where I had the privilege of developing multiple transformational drugs for people with cancer and blood…
After 21 amazing years at Roche/Genentech, where I had the privilege of developing multiple transformational drugs for people with cancer and blood…
Liked by Huibin Yue
Other similar profiles
Explore collaborative articles
We’re unlocking community knowledge in a new way. Experts add insights directly into each article, started with the help of AI.
Explore MoreOthers named Huibin Yue
-
Huibin Yue
Sr Statistical Scientist at Genentech
-
岳慧彬
大连马勒润滑油有限公司 - 总经理
-
岳会彬
总经理 - 新兴能源装备股份股份有限公司合肥分公司
-
岳慧斌
--
8 others named Huibin Yue are on LinkedIn
See others named Huibin Yue